Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Oct;8(5):902-914.
doi: 10.21037/jgo.2017.07.06.

Adaptive radiation dose escalation in rectal adenocarcinoma: a review

Jonathan D Van Wickle  1 , Eric S Paulson  1 , Jerome C Landry  2 , Beth A Erickson  1 , William A Hall  1
Affiliations
Review

Adaptive radiation dose escalation in rectal adenocarcinoma: a review

Jonathan D Van Wickle et al. J Gastrointest Oncol. 2017 Oct.

Abstract

Total mesorectal excision (TME) after neoadjuvant chemoradiotherapy (CRT) has offered superior control for patients with locally advanced rectal cancer, but can carry a quality of life cost. Fortunately, some patients achieve a complete response after CRT alone without the added morbidity caused by surgery. Efforts to increase fidelity of radiation treatment planning and delivery may allow for escalated doses of radiotherapy (RT) with limited off-target toxicity and elicit more pathological complete responses (pCR) to CRT thereby sparing more rectal cancer patients from surgery. In this review, methods of delivering escalated RT boost above 45-50.4 Gy are discussed including: 3D conformal, intensity-modulated radiotherapy (IMRT), and brachytherapy. Newly developed adaptive boost strategies and imaging modalities used in RT planning and response evaluation such as magnetic resonance imaging (MRI) and positron emission tomography (PET) are also discussed.

Keywords: Rectal cancer; adaptive dose escalation; radiotherapy; rectal organ preservation.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Elekta Inc. provides research support to the Medical College of Wisconsin Department of Radiation Oncology. In addition, WA Hall, MD reports research support from the American Cancer Society and the National Institutes of Health.

References

    1. Peeters KC, Marijnen CA, Nagtegaal ID, et al. The TME trial after a median follow-up of 6 years: increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma. Ann Surg 2007;246:693-701. 10.1097/01.sla.0000257358.56863.ce - DOI - PubMed
    1. Sauer R, Liersch T, Merkel S, et al. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol 2012;30:1926-33. 10.1200/JCO.2011.40.1836 - DOI - PubMed
    1. Luna-Perez P, Rodriguez-Ramirez S, Vega J, et al. Morbidity and mortality following abdominoperineal resection for low rectal adenocarcinoma. Rev Invest Clin 2001;53:388-95. - PubMed
    1. Habr-Gama A, Perez RO, Nadalin W, et al. Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results. Ann Surg 2004;240:711-7; discussion 717-8. - PMC - PubMed
    1. Habr-Gama A, Perez RO, Proscurshim I, et al. Patterns of failure and survival for nonoperative treatment of stage c0 distal rectal cancer following neoadjuvant chemoradiation therapy. J Gastrointest Surg 2006;10:1319-28; discussion 1328-9. 10.1016/j.gassur.2006.09.005 - DOI - PubMed